ClinicalTrials.gg
Not yet recruitingNCT05642949Updated Jan 9, 2023

Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of MHB036C in Advanced Solid Tumor, sponsored by Minghui Pharmaceutical Pty Ltd. Not yet recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-09.

Sponsored by Minghui Pharmaceutical Pty Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety, pharmacokinetics, and anti-tumor efficacy of MHB036C in participants with advanced or metastatic solid tumors.

Read the detailed description

This study is the first-in-human (FIH) trial of MHB036C, and contains two parts: dose escalation phase (part one) and dose expansion phase (part two).

The dose escalation phase is an open-label, multi-center study in which eligible participants with advanced or metastatic solid tumors will be enrolled to receive MHB036C monotherapy. This study is designed to assess the safety and tolerability of MHB036C in participants with advanced or metastatic solid tumors, to determine the maximum tolerated dose (MTD) of MHB036C, and to assess its pharmacokinetic profile and preliminary efficacy.

The dose expansion part is an open-label, multi-center, multi-cohort expansion study in which participants with advanced or metastatic solid tumors of some predefined cancer types will be enrolled to receive MHB036C monotherapy. Participants with same types of solid tumors will be randomized assigned into different selected dose groups, and will be treated with the corresponding dose. This study is designed to assess the preliminary efficacy and safety of MHB036C monotherapy in subjects with some types of advanced or metastatic solid tumors, so as to determine the recommended phase 2 dose (RP2D); and to assess the immunogenicity and pharmacokinetic profiles of MHB036C.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Minghui Pharmaceutical Pty Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants enrolled must meet all of the following criteria:

General conditions

  1. Participants voluntarily agree to participate in the study and sign the Form (ICF).
  2. Participants aged 18 years or older (inclusive), without gender limitation.
  3. Participants with performance score of 0 \~ 1.
  4. Participants with expected survival time of more than 3 months.
  5. Eligible participants of (males and females) must agree to take reliable measures (hormone or barrier method, or absolute abstinence, etc.) with their partners during the study and within at least 90 days after the last dose; female participants of childbearing potential must have a negative results of blood pregnancy test within 7 days before the first dose of the product, and must be non-lactating.
  6. Participants who are able to understand study requirements, and willing and able to comply with arrangements of study and follow-up procedures.

    Neoplasm-related criteria

  7. Participants to be enrolled in part one must have or cytologically confirmed advanced or solid tumors, which have failed or are intolerant to standard of care (SOC), or for which no SOC is available;
  8. Participants to be enrolled in part two must have histologically or cytologically confirmed advanced or metastatic solid tumors, including but not limited to the following types: non-small cell lung cancer (NSCLC); small cell lung cancer (SCLC); pancreatic ductal adenocarcinoma (PDAC); head and neck squamous cell carcinoma (HNSCC); esophageal squamous cell carcinoma (ESCC); urothelial carcinoma (UC); ovarian cancer (OC); endometrial cancer (EC); breast cancer (BC); gastric cancer (GC); castration-resistant prostate cancer (CRPC); sweat gland carcinoma (SGC).

    1. Additional criteria for enrollment of participants with NSCLC:

      • Participants with unresectable advanced NSCLC who have failed standard of care with platinum doublet chemotherapy and immune- (ICIs), and are not suitable for radical therapy (NSCLC participants with driver gene mutations should have failed or are intolerant to targeted therapy for the corresponding driver gene mutation, or unsuitable for the corresponding targeted therapy as per investigator's evaluation ).
    2. Additional criteria for enrollment of participants with SCLC:

      • Participants with unresectable or metastatic SCLC who have previously received at least one , including platinum-based chemotherapy and immune-checkpoint inhibitors (ICIs)
    3. Additional criteria for enrollment of participants with PDAC:

      • Participants with unresectable or metastatic PDAC who have previously received at least one line of systemic chemotherapy, including any stage in /adjuvant/ palliative therapy
    4. Additional criteria for enrollment of participants with HNSCC:

      • Participants with unresectable advanced or metastatic HNSCC who have previously received at least one line of systemic chemotherapy, including platinum-based chemotherapy and ICIs (combined or sequential therapy).
    5. Additional criteria for enrollment of participants with ESCC:

      • Participants with unresectable or metastatic ESCC who have previously received at least one line of systemic chemotherapy (platinum-based chemotherapy).
    6. Additional criteria for enrollment of participants with UC:

      • Participants with unresectable, locally progressed, or metastatic (histologically including transitional cells and mixed of transitional/non-transitional cells) UC (sites of occurrence including renal pelvis, ureter, bladder, and urethra) who have previously received at least one line of chemotherapy, including platinum-based chemotherapy and ICIs (combined or sequential therapy).
    7. Additional criteria for enrollment of participants with OC:

      • Participants with OC (including rare types of epithelial ovarian cancer stipulated in the NCCN guidelines as well as fallopian tube cancer and primary peritoneal cancer) who had tumor recurrence or metastasis after receiving at least one line of platinum-based chemotherapy
    8. Additional criteria for enrollment of participants with EC:

      • Participants with recurrent or incurable EC who had tumor recurrence or progression following previous radical therapy, and subsequently received therapies including standard systemic therapy.
    9. Additional criteria for enrollment of participants with BC:

      • For participants with advanced/unresectable or metastatic TNBC: Participants who have received at least 1 line of systemic chemotherapy with anthracyclines and taxanes included in the prior systemic therapy (regardless of neoadjuvant/adjuvant/palliative therapy).
      • For BC participants with hormone receptor (HR) positive (ER+ and/or PR+) and expression negative (IHC 0, 1+ or IHC 2+ with ISH-): Participants who are intolerant or resistant to endocrine therapy, or unsuitable for endocrine therapy as per investigator's evaluation.
      • For BC participants with HER2 expression positive (IHC 3+ or IHC 2+ with ISH+): Participants who have previously received at least 1 line of therapy, which included HER2-targeted therapy.
    10. Additional criteria for enrollment of participants with GC:

      • Participants with unresectable or metastatic GC who have previously received at least one line of standard systemic chemotherapy, while the previous treatment regimens of HER2-positive (IHC 3+ or IHC 2+ with ISH+) participants must include HER2-targeted therapy.
    11. Additional criteria for enrollment of participants with CRPC:

      • Absence of neuroendocrine differentiation or small cell histology confirmed by histopathology;
      • Underwent surgical or medical castration, with testosterone levels below 50 ng/dL;
      • Objective progression as determined by radiographic progression after androgen deprivation therapy;
      • Participants has or progressed after receiving at least one of the following medications: abiraterone, enzalutamide, apalutamide, or darolutamide;
      • Participants has relapsed or progressed after previously docetaxel-based or mitoxantrone-based cytotoxic chemotherapy for metastatic CRPC;
      • Participants with at least 1 documented lesion confirmed by either a bone scan or a CT/MRI scan.
    12. Sweat gland carcinoma (SGC): unresectable or metastatic SGC.
  9. Participants who agree to provide the pre-treatment tumor tissue samples for retrospective testing of target expression and other biomarkers (participants who agree but are unable to provide pre-treatment tumor tissue sample may also be enrolled). Expression of target in tumor tissue samples collected from participants will not be used as a criterion for participant enrollment.
  10. Participants with at least one measurable tumor lesion as per v1.1 (generally, tumor lesions located in a previously irradiated areas or other locoregional treatment sites will not be considered as , unless the lesions have clearly progressed or still persist three months after radiotherapy); for participants with CRPC, evaluable lesions as defined by PCWG3 criteria, or at least one measurable tumor lesion as per RECIST v1.1 are required.

    Adequate bone marrow reserve and organ functions:

  11. Adequate bone marrow reserve (without transfusion, treatment of colony-stimulating factor, or biologics with similar effects within 7 days prior to the screening);

    • (ANC) ≥ 1.5 × 109/L;
    • count ≥ 100 × 109/L;
    • ≥ 9.0 g/dL.
  12. Adequate hepatic function (with reference to normal values specified by the clinical study site):

    • Total (TBIL) ≤ 1.5 × (ULN); TBIL ≤ 2.0 × ULN if Gilbert's syndrome is present; TBIL ≤ 3.0 × ULN is permitted if direct bilirubin (DBIL) suggests extrahepatic obstruction.
    • For participants with non-hepatic tumors and without hepatic metastases, (AST) and alanine aminotransferase (ALT) shall be ≤ 3.0 × ULN; for participants with hepatic tumors or hepatic metastases, AST and ALT shall be ≤ 5.0 × ULN;
  13. Adequate renal function (with reference to normal values specified by the clinical study site):

    • Creatinine (Cr) ≤ 1.5 × ULN; when Cr > 1.5 × ULN, only participants with (Ccr) ≥ 50 mL/min can be enrolled (using Cockcroft-Gault formula);
  14. Adequate coagulation function:

    • (APTT) ≤ 1.5 × ULN, and international normalized ratio (INR) ≤ 1.5.
  15. Adequate cardiac function:

    • (LVEF) ≥ 50% by echocardiogram within 28 days prior to enrollment;
    • (NYHA) Class \< grade 3.

Exclusion criteria

Exclusion Criteria:

Participants will be not enrolled if they meet any of the following exclusion criteria:

Neoplasm-related criteria:

  1. Participants with 2 or more (except effectively treated non-melanoma skin cancer, cervical carcinoma in situ or other tumors, or malignancies considered cured) within 5 years prior to sign the Form.
  2. Participants who have received chemotherapy within 3 weeks prior to the first dose of product, or have received target therapy within 2 weeks prior to the first dose, or have received anti-tumor therapy including radiation therapy, biologic therapy, endocrine therapy, immunotherapy, etc. within 4 weeks prior to the first dose; or participants with the following conditions:

    • Medication of nitrosourea or mitomycin C within 6 weeks prior to the first dose of MHB036C;
    • Medication of oral fluoropyrimidines or small molecule targeted agents within 5 half-lives of such drug before first dose of investigational product.
    • Medication of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose of investigational product.
  3. Medication of other unmarketed investigational products or therapies within 4 weeks prior to the first dose of investigational product.
  4. Presence of and/or carcinomatous meningitis. Participants previously treated for brain metastases may be considered to be enrolled in this study, provided they have been in stable condition for at least 1 month, have no progression confirmed by radiographic examination within 4 weeks prior to the first dose of investigational product, all neurological symptoms have recovered, no evidence of new or enlarging brain metastases, and radiation or surgical had been discontinued for at least 14 days prior to the first dose of investigational product, or with therapy ≤10 mg/day prednisone or equivalent dose of similar drugs within 14 days prior to the first dose of investigational product or during the study. This exception does not include carcinomatous meningitis, which should be excluded regardless of clinical stability.
  5. Participants previously received same targeted therapy will be excluded.
  6. Participants with adverse reactions from previous anti-tumor therapy that have not recovered to ≤Grade 1 as per 5.0 (except for toxicities without safety risks as determined by the investigator, such as alopecia, hypothyroidism stably managed by hormone replacement therapy, etc.).

    General conditions:

  7. Participants underwent major organ surgery (excluding ) or significant trauma within 4 weeks prior to the first dose of investigational product or require elective surgery during the study.
  8. Participants vaccinated with attenuated (except for SARS-CoV-2 vaccination) within 4 weeks prior to the first dose of investigational product.
  9. Participants received treatment with systemic corticosteroids (prednisone at > 10 mg/day, or similar drugs at equivalent dose) or other agents within 14 days prior to the first dose of investigational product, with the following exceptions:

    • Treatment with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids;
    • Short-term use of glucocorticoids for prophylaxis (e.g., prevention of contrast media allergy).
  10. Participants with clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any , connective tissue or inflammatory disorders with pulmonary involvement, or prior pneumonectomy.
  11. Participants with history of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis that cannot be ruled out by imaging examination at screening.
  12. Participants with active pulmonary tuberculosis.
  13. Participants with clinically diagnosed corneal disease.
  14. Participants with current active infection requiring systemic therapy.
  15. Participants with positive results in virus serology tests (participants receiving antiviral prophylaxis other than interferon are allowed to be enrolled):

    • anti- antibody positive;
    • Or, positive results of both and HBV-DNA (i.e., HBV-DNA result is not below the LOD);
    • Or, positive results of both Ab and HCV-RNA (i.e., HCV-RNA result is not below the LOD).
  16. History of serious cardiovascular and cerebrovascular diseases, including but not limited to:

    • Severe heart rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, or second-degree to third-degree atrioventricular block;
    • Fridericia- interval (QTcF) > 450 ms for males or > 470 ms for females;
    • Acute coronary syndrome, congestive heart failure, aortic dissection, stroke and other major cardiovascular and cerebrovascular events within 6 months prior to the first dose;
    • New myocardial infarction or unstable angina within 6 months prior to enrollment;
    • Clinically uncontrolled hypertension;
  17. Participants with active autoimmune disorders (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except for participants with clinically stable autoimmune thyroid disease or type I diabetes mellitus.
  18. Participants with clinically uncontrolled effusion in third spacing, deemed as inappropriate for enrollment by the investigator.
  19. Participants known to have or delayed hypersensitivity to certain components or analogues of the study drug.
  20. Participants with drug abuse or any other medical conditions, such as cardiac or psychological conditions that, in the opinion of the investigator, may interfere with study participation or the results of the clinical study.
  21. Participants known to have alcohol or drug abuse.
  22. Females who are pregnant or lactating, or males/females who plan for childbirth.
  23. Participants who are estimated to have poor compliance in study participation, or unsuitable to participate this clinical study by the opinion of the investigator for the history of other serious systemic disorders, or with other reasons.
Terms in these criteria, in plain language(38)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Dose Escalation - All Participants

    All participants enrolled in the dose escalation part.

    Drug: MHB036C

  • Experimental
    Dose Expansion - All Participants

    All participants enrolled in the dose expansion part

    Drug: MHB036C

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Adverse events was assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: From the day of the first dose of MHB036C to 30 days after the day of the last dose of MHB036C

  2. Number of participants with dose-limiting toxicities

    Dose-limiting toxicities are defined as side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment

    Time frame: 21 days after the first dose of MHB036C

Secondary outcomes

  1. Pharmacokinetics (PK) parameter: Maximum concentration (Cmax)

    Categories: MHB036C, total antibody, free toxin MH30010008

    Time frame: Within 5 cycles (each cycle is 21 days)

  2. PK parameter: Time to maximum concentration (Tmax)

    Categories: MHB036C, total antibody, free toxin MH30010008

    Time frame: Within 5 cycles (each cycle is 21 days)

  3. PK parameter: Area under the concentration-time curve (AUC)

    Categories: MHB036C, total antibody, free toxin MH30010008

    Time frame: Within 5 cycles (each cycle is 21 days)

  4. PK parameter: Trough concentration (Ctrough)

    Categories: MHB036C, total antibody, free toxin MH30010008

    Time frame: Within 5 cycles (each cycle is 21 days)

  5. PK parameter: Terminal or apparent terminal half-life (t1/2)

    Categories: MHB036C, total antibody, free toxin MH30010008

    Time frame: Within 5 cycles (each cycle is 21 days)

  6. PK parameter: Systemic clearance (CL)

    Categories: MHB036C, total antibody, free toxin MH30010008

    Time frame: Within 5 cycles (each cycle is 21 days)

  7. Immunogenicity Assessment

    Assessment of anti-drug antibody (ADA)

    Time frame: Within 5 cycles (each cycle is 21 days)

  8. Objective Response Rate (ORR)

    Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)

    Time frame: 24 months

  9. Duration of Response (DOR)

    DOR was defined as the time from first assessment of PR or CR until disease progression.

    Time frame: 24 months

  10. Disease Control Rate (DCR)

    DCR was defined as the proportion of participants with a complete response (CR), partial response (PR) or stable disease (SD).

    Time frame: 24 months

  11. Progression Free Survival (PFS)

    Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: 24 months

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2023; primary completion for Dec 2025, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 8, 2022
StartEst.
Jan 23, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Jan 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05642949
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Jan 23, 2023 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jan 9, 2023

Study contacts

Minghui Pharmaceutical Contact for Clinical Trial Information
Contact
minghui_ra@minghuipharma.com
086-02160898367

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036C

Start the discussion